No Data
Maipu Medical: Report for the third quarter of 2024
Meipu Medical (301033.SZ): Achieved revenue of 0.191 billion yuan in the first three quarters, a year-on-year increase of 30.98%.
Great Wisdom reported on October 28th that Maipu Medical (301033.SZ) released the third quarter report for 2024, with the company achieving revenue of 0.191 billion yuan in the first three quarters, a 30.98% year-on-year increase; the net income attributable to shareholders of the listed company was 52.803 million yuan, a 107.68% year-on-year increase; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 46.0877 million yuan, a 108.37% year-on-year increase; and the basic earnings per share were 0.80 yuan. The increase in revenue is mainly due to the company orderly carrying out work around the operational objectives set at the beginning of the year, with an increase in marketing efforts.
Returns On Capital Are Showing Encouraging Signs At Medprin Regenerative Medical Technologies (SZSE:301033)
Mai Pu Medical (301033.SZ) subsidiary obtained EU MDR certification for three products.
Meipu Medical (301033.SZ) announced that its subsidiary, Meipu Biotechnology (Germany) Co., Ltd., has three products...
Medprin Regenerative Medical Technologies: Half-year report for the year 2024.
Medprin Regenerative Medical Technologies: Summary of Half-Year Report in 2024.
Medprin Regenerative Medical Technologies Co., Ltd. (SZSE:301033) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?